Bridgefront Capital LLC Buys Shares of 11,994 Exact Sciences Corporation $EXAS

Bridgefront Capital LLC bought a new position in Exact Sciences Corporation (NASDAQ:EXAS) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 11,994 shares of the medical research company’s stock, valued at approximately $656,000.

Several other institutional investors have also recently made changes to their positions in EXAS. Ameriprise Financial Inc. lifted its stake in Exact Sciences by 105.8% in the third quarter. Ameriprise Financial Inc. now owns 4,493,085 shares of the medical research company’s stock worth $245,802,000 after acquiring an additional 2,310,139 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Exact Sciences by 31.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,909,501 shares of the medical research company’s stock valued at $213,889,000 after purchasing an additional 939,888 shares in the last quarter. William Blair Investment Management LLC raised its holdings in shares of Exact Sciences by 26.5% in the 3rd quarter. William Blair Investment Management LLC now owns 2,555,051 shares of the medical research company’s stock valued at $139,787,000 after purchasing an additional 534,881 shares in the last quarter. Champlain Investment Partners LLC lifted its position in shares of Exact Sciences by 12.6% in the 2nd quarter. Champlain Investment Partners LLC now owns 2,529,820 shares of the medical research company’s stock worth $134,435,000 after purchasing an additional 282,825 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Exact Sciences by 12.3% during the third quarter. Dimensional Fund Advisors LP now owns 2,188,864 shares of the medical research company’s stock valued at $119,732,000 after purchasing an additional 239,313 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on EXAS. Wolfe Research lowered shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th. Stifel Nicolaus restated a “hold” rating and set a $105.00 target price (up from $80.00) on shares of Exact Sciences in a report on Friday, November 28th. Craig Hallum cut Exact Sciences from a “buy” rating to a “hold” rating and set a $105.00 target price on the stock. in a research report on Friday, November 21st. Wells Fargo & Company reissued an “equal weight” rating and issued a $105.00 price target (up from $85.00) on shares of Exact Sciences in a research report on Thursday, November 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a research note on Thursday, January 22nd. Twenty-one research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Exact Sciences has an average rating of “Reduce” and an average price target of $92.13.

Exact Sciences Trading Up 0.3%

NASDAQ:EXAS opened at $103.57 on Monday. Exact Sciences Corporation has a 52 week low of $38.81 and a 52 week high of $103.75. The firm has a 50 day moving average of $102.83 and a 200 day moving average of $84.12. The company has a quick ratio of 2.17, a current ratio of 2.43 and a debt-to-equity ratio of 0.97. The stock has a market capitalization of $19.77 billion, a price-to-earnings ratio of -94.15, a PEG ratio of 2.36 and a beta of 1.41.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.Exact Sciences’s revenue was up 23.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.06) earnings per share. As a group, sell-side analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.